Connective attracts 14 billion won in investment

Connecteve has completed a Series A investment round totaling 14 billion won. A total of 9 venture capitals (VCs) participated in this round, with existing investors DSC Investment, Schmidt, Stonebridge Investment, and Reventures participating as follow-on investors, and BSK Investment, TS Investment, IMM Investment, JB Investment, and Big Move Ventures joining as new investors. Connecteve, which has built a strong investment network through this, has raised expectations for future technological advancements and market expansion.

This investment is the result of a high evaluation of Connective’s unique technological prowess and future growth potential amid the global economic slowdown and shrinking venture investment market. In particular, expectations are reflected for AI-based medical solutions scheduled to be released this year, such as CONNEVO KOA, ALI, and Suite, which are expected to lead innovative changes in the medical field. These products are expected to suggest a new paradigm in medicine by supporting patient-tailored treatment plans using artificial intelligence and providing precise analysis tools to orthopedic surgeons.

Additionally, Connective is developing a next-generation artificial joint surgery robot scheduled for release in 2027. This robot will significantly improve existing robotic surgery technology based on innovative surgical technology using the VISION AI system, and will also enable automatic surgical design using artificial intelligence.

With this investment, Connective plans to launch full-scale commercialization based on its research and development achievements to date. It has already secured major domestic hospitals as its main customers, and in particular, Bumin Hospital with over 670 beds will participate in this round as a strategic investor (SI) and participate in commercialization.

Noh Du-hyeon, CEO of Connective, said, “We are developing a patient-tailored treatment and orthopedic surgery support system using AI technology, and we aim to provide innovative solutions that provide practical help to both patients and medical staff. With this investment, we will further strengthen our research and development for entry into the global market and lead the new paradigm of AI and medical robot technology.”

• See more related articles